Montelukast Vir (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Vir, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for the management of asthma and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured manufacturing and distribution networks across the EU and other regulated markets, and the product meets EU pharmacopeial standards and is available for bulk procurement globally.

Montelukast Vir is a leukotriene receptor antagonist used to manage conditions driven by leukotriene‑mediated inflammation.

- Asthma: improves control of chronic asthma and reduces exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by seasonal allergies. - Exercise‑induced bronchoconstriction: prevents airway narrowing during or after physical activity.

Montelukast may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Abdominal pain: discomfort or cramping in the stomach area. - Cough: transient irritation of the throat. - Nausea: feeling of queasiness without vomiting.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue or throat. - Stevens‑Johnson syndrome: severe skin rash with blistering. - Mood changes: including depression, anxiety, or suicidal thoughts.

Before prescribing Montelukast Vir, clinicians should consider several safety aspects.

- Liver function monitoring: assess hepatic enzymes in patients with liver disease. - Neuropsychiatric assessment: watch for mood alterations or suicidal ideation. - Severe hepatic impairment: use with caution and adjust therapy as needed. - Hypersensitivity: avoid in individuals with known allergy to montelukast or excipients. - Concomitant medication review: evaluate for potential drug interactions. - Store at ambient temperature: keep in the original pack, protect from moisture.

Montelukast Vir can interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Phenobarbital: induces metabolism, reducing montelukast exposure. - Rifampin: strong enzyme inducer that lowers drug levels. - Ketoconazole: potent CYP3A4 inhibitor that may increase montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, requiring coagulation monitoring. - Theophylline: may affect plasma levels, necessitating dose adjustment. - Beta‑agonists: concurrent use may diminish bronchodilator response.